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Table S10 -Summary of targets for which compound 1 has significant activity. S14 tranylcypromine. An excess of substrate was added after 20 minutes. The measured fluorescence increased for compounds 1a and 3, as expected for reversible inhibition, whereas only a small increase was observed for tranylcypromine that was used as control. 
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C05262984 (L) Enamine b Number of PubChem bioassays in which the tested compound was annotated as active and had an activity value < 10 µM or response >50% at this concentration. The identified targets for compound 1 (curated set) are summarized in Table S10 . 7 , leading to false positives such assays. The assays performed in this study were not dependent on luciferase.
